Jakavi 20 mg Tablet is a prescription medication used to treat certain types of blood disorders. Jakavi 20 mg tablet is specifically used to treat adults with certain types of myelofibrosis (a type of bone marrow disorder) and polycythemia vera (a blood disorder characterized by an overproduction of red blood cells). A blood cell count must be performed before initiating therapy with Jakavi. Jakavi 20 mg tablet is not recommended for use in patients under 12 years of age safety and efficacy are not established.
Polycythemia Vera: Jakavi 20 mg tablet is used in the treatment of polycythemia vera is a rare blood disorder in which the body produces too many red blood cells. The excess red blood cells can cause the blood to become thick and sticky, making it harder to flow through the vessels. This can lead to a number of complications, including an increased risk of blood clots that can cause a heart attack or stroke.
Chronic idiopathic myelofibrosis: Jakavi 20 mg tablet is used in the treatment of chronic idiopathic myelofibrosis (also called primary myelofibrosis) is a type of bone marrow disease in which the bone marrow is replaced by scar tissue, resulting in a decrease in the production of blood cells. The scar tissue can also lead to the accumulation of excess fluid in the abdomen (ascites) and the accumulation of fat cells in the liver and spleen.
Jakavi 20 mg tablet can be effective in reducing symptoms associated with myelofibrosis, such as fatigue, enlarged spleen, and uncontrolled bleeding.
Jakavi 20 mg tablet may improve the overall quality of life and reduce the symptoms of myelofibrosis.
Jakavi has been shown to reduce bone marrow fibrosis (scarring) in those with myelofibrosis.
Jakavi 20 mg tablet prevent cancer in those with myelofibrosis and help to prevent the progression of myelofibrosis to acute myeloid leukaemia (AML).
Like all medication,
Jakavi 20 mg tablet may be taken with or without food. Take it at the same time each day. Swallow the tablet whole with a full glass of water. Do not crush, chew, or open the tablet. If you forget to take a dose, make up for it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
Jakavi belongs to the class of drugs known as Janus kinase inhibitors (JAK). The action of Jakavi 20 mg tablet is based on inhibiting the activity of certain proteins called JAKs, which play a role in signalling pathways that regulate the production of certain proteins in the body. By inhibiting these proteins, Jakavi may help reduce inflammation and improve symptoms in certain diseases such as myelofibrosis and polycythemia vera.
Jakavi 20 mg tablet may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Jakavi.
It is not recommended to breastfeed while taking Jakavi. Jakavi 20 mg tablet may pass into breast milk and harm the infant. If you are breastfeeding and taking Jakavi 20 mg tablet, it is important to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.
Use of Jakavi 20 mg tablet may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Jakavi 20 mg tablet during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
It is not recommended to consume alcohol while taking Jakavi 20 mg tablet. Alcohol may increase the risk of side effects or interfere with the effectiveness of the Jakavi 20 mg tablet. It is best to talk to your doctor or pharmacist before consuming alcohol while taking any medicine.
Jakavi 20 mg tablet should be used with caution in patients with Kidney disease. It is important that patients with kidney disease closely monitor kidney function while taking Jakavi 20 mg tablet and report any unusual symptoms or changes in kidney function to their doctor. The dose of Jakavi may need to be adjusted in patients with kidney disease.
Jakavi 20 mg tablet should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Jakavi 20 mg tablet and report any unusual symptoms or changes in liver function to their doctor. The dose of Jakavi may need to be adjusted in patients with liver disease.
1. Jakafi, (ruxolitinib) Tablets, For Oral Use, Incyte Corporation, Product Leaflet
2. Ruxolitinib 5 Mg, 10 Mg, 15 Mg And 20 Mg Tablets, Novartis Healthcare Pvt. Ltd, Product Monograph
3. Jakavi Tablets: 5 Mg, 10 Mg, 15 Mg And 20 Mg, Novartis New Zealand Limited, Product Leaflet
4. Jakavi, Novartis Pharma Ag, Basel, Switzerland, Product Leaflet